GS-9256 is an inhibitor of HCV NS3 protease with a macrocyclic structure and novel phosphinic acid pharmacophore.
Methods
Key preclinical properties of GS-9256 including in vitro antiviral activity, cross-resistance and pharmacokinetic properties were investigated in non-human species.
Results
In genotype (GT) 1b Huh-luc cells with a replicon encoding luciferase, GS-9256 had a mean 50% effective concentration (EC50) value of 20.0 nM, with minimal cytotoxicity. Antiviral activity was similar in a number of additional GT1b and GT1a replicon cell lines. Similar potency was observed in chimeric replicons encoding the NS3 protease of GT1 clinical isolates. GS-9256 was less active in GT2a replicon cells (14.2-fold increase in EC50). Additive to synergistic in vitro antiviral activity was observed when GS-9256 was combined with other agents including interferon-α, ribavirin, NS5B polymerase inhibitors GS-6620 and tegobuvir, as well as the NS5A inhibitor ledipasvir. GS-9256 retained wild-type activity against all tested NS5B and NS5A inhibitor resistance mutations. GS-9256 was metabolically stable in microsomes and hepatocytes of tested species, including rodents, dogs and humans. GS-9256 had high bioavailability in mice (near 100%) and moderate bioavailability in rats (14%), dogs (21%) and monkeys (14%). Elimination half-lives were approximately 2 h in mice, 0.6 h in rats, 5 h in dogs and 4 h in monkey. A study in bile duct-cannulated rats indicated that the major route of elimination is through biliary excretion of unmetabolized GS-9256.
Conclusions
GS-9256 showed a favourable preclinical profile supportive of clinical development for the treatment of chronic HCV infection in GT1 patients.
References
1.
GallinariP., BrennanD., NardiC.Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus.J Virol1998; 72: 6758–6769.
2.
LindenbachB.D., RiceC.M.Unravelling hepatitis C virus replication from genome to function.Nature2005; 436: 933–938.
3.
LiK., FoyE., FerreonJ.C.Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.Proc Natl Acad Sci U S A2005; 102: 2992–2997.
4.
LiX.D., SunL., SethR.B., PinedaG., ChenZ.J.Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.Proc Natl Acad Sci U S A2005; 102: 17717–17722.
5.
LamarreD., AndersonP.C., BaileyM.An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.Nature2003; 426: 186–189.
6.
LiangT.J., GhanyM.G.Current and future therapies for hepatitis C virus infection.N Engl J Med2013; 368: 1907–1917.
7.
KowdleyK.V., LawitzE., PoordadF.Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.N Engl J Med2014; 370: 222–232.
8.
LawitzE., SulkowskiM.S., GhalibR.Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.Lancet2014; 384: 1756–1765.
9.
ShengX.C., CasarezA., CaiR.Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity.Bioorg Med Chem Lett2012; 22: 1394–1396.
10.
GoldwaterR., DeMiccoM., ZongJ.Safety, pharmacokinetics and antiviral activity of single oral doses of the HCV NS3 protease inhibitor GS-9256.61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 29 October–2 November 2010, Boston, MA, USA. Poster abstract 824.
11.
LawitzE.J., MarburyT.C., VinceB.D.Dose-ranging, three-day monotherapy study of the HCV NS3 protease inhibitor GS-9256.J Hepatol2010; 52Suppl 1: S466–S467.
12.
ZeuzemS., BuggischP., AgarwalK.The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.Hepatology2012; 55: 749–758.
13.
NelsonD., LawitzE., BainV.High SVR12 with 16 weeks of tegobuvir and GS-9256 plus peginterferon-alfa2a and ribavirin in treatment-naive genotype 1 HCV patients.J Hepatol2012; 56: S6–S7.
14.
VrolijkJ.M., KaulA., HansenB.E.A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.J Virol Methods2003; 110: 201–209.
15.
ZhuQ., GuoJ-T, SeegerC.Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells.J Virol2003; 77: 9204–9210.
16.
PaulsonM.S., YangH., ShihI.H.Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus.Antiviral Res2009; 83: 135–142.
RobinsonM., TianY., DelaneyW.E., GreensteinA.E.Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals.Proc Natl Acad Sci U S A2011; 108: 10290–10295.
19.
QiX., BaeA., LiuS.Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.Antiviral Res2009; 81: 166–173.
20.
LohmannV., KornerF., KochJ., HerianU., TheilmannL., BartenschlagerR.Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.Science1999; 285: 110–113.
21.
YangH., RobinsonM., CorsaA.C.Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.Antimicrob Agents Chemother2014; 58: 647–653.
22.
YangH., DelaneyW.E.A novel fluorescence-based protease assay using the endogenous NS3/4A protease activity present in the total cell lysates of HCV replicon cells.J Clin Virol2006; 36Suppl 2: S109–S110.
DelaneyW.E., EdwardsR., ColledgeD.Cross-resistance testing of antihepadnaviral compounds using novel hepatitis B virus baculoviruses encoding drug-resistant strains of hepatitis B virus.Antimicrob Agents Chemother2001; 45: 1705–1713.
25.
PrichardM.N., AseltineK.R., ShipmanC.Jr.. MacSynergy™ II, Version 1.0.University of MichiganAnn Arbor, Michigan; 1993.
26.
PrichardM.N., PrichardL.E., ShipmanC.Jr.. Strategic design and three-dimensional analysis of antiviral drug combinations.Antimicrob Agents Chemother1993; 37: 540–545.
27.
PrichardM.N., ShipmanC.Jr.. A three-dimensional model to analyze drug-drug interactions.Antiviral Res1990; 14: 181–205.
28.
PrichardM.N., ShipmanC.Jr.. Analysis of combinations of antiviral drugs and design of effective multidrug therapies.Antivir Ther1996; 1: 9–20.
29.
MoH., YangC., WangK.Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.J Viral Hepat2011; 18: 338–348.
30.
MurakamiE., WangT., BabusisD.Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620.Antimicrob Agents Chemother2014; 58: 1943–1951.
31.
ArturssonP.Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells.J Pharm Sci1990; 79: 476–482.
32.
ChoA., ZhangL., XuJ.Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients.J Med Chem2014; 57: 1812–1835.
33.
ShihI.H., VliegenI., PengB.Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.Antimicrob Agents Chemother2011; 55: 4196–4203.
34.
FenauxM., EngS., LeavittS.A.Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.Antimicrob Agents Chemother2013; 57: 804–810.
35.
SarrazinC., KiefferT.L., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.Gastroenterology2007; 132: 1767–1777.
36.
SarrazinC., ZeuzemS.Resistance to direct antiviral agents in patients with hepatitis C virus infection.Gastroenterology2010; 138: 447–462.
37.
FridellR.A., WangC., SunJ.H.Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.Hepatology2011; 54: 1924–1935.
38.
SvarovskaiaE.S., MartinR., McHutchisonJ.G., MillerM.D., MoH.Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy.J Clin Microbiol2012; 50: 3267–3274.
